Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 11/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571449 | 0.89 | MTNR1B (0.43) | MTNR1BHTR4NPC1ALDH1A1SLC9A1 | |
| SCHEMBL1572199 | 0.78 | HTR4 (0.50) | HTR4CNR1CNR2 | |
| SCHEMBL1340659 | 0.74 | MTNR1B (0.43) | MTNR1BHTR4NPC1ALDH1A1SLC9A1 | |
| SCHEMBL924740 | 0.71 | MTNR1B (0.38) | MTNR1BHTR4 | |
| SCHEMBL14640388 | 0.71 | CHRM1 (0.49) | HTR4 | |
| SCHEMBL30184431 | 0.71 | MTNR1B (0.50) | MTNR1BHTR4MTNR1A | |
| SCHEMBL30292443 | 0.68 | POLB (0.48) | MTNR1BMTNR1A | |
| SCHEMBL923968 | 0.68 | HIF1A (0.50) | — | |
| SCHEMBL10375846 | 0.68 | HTR4 (0.53) | HTR4CNR1CNR2 | |
| SCHEMBL29133954 | 0.67 | MTNR1B (0.46) | MTNR1BNPC1SLC9A1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009461-A1 | 2-AZA-BICYCLO[3.3.0]OCTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009461-A1 | 2-AZA-BICYCLO[3.3.0]OCTANE DERIVATIVES | HCRTR2, HCRTR1, NPY2R | MTNR1B 74/4885HTR4 279/4885NPC1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.